December 6, 2012 10:33 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Oppenheimer initiated coverage on Cleveland BioLabs (NASDAQ: CBLI) with an Outperform rating and a $3 price target. Oppenheimer commented, "Biodefense drug development has a unique risk/reward risk profile. On the positive side, there is nondilutive capital from the government to cover R&D, no need for marketing/salesforce since government is generally the primary buyer, and the safety data from biodefense (paid by government) can be used for other indications of the drug. … Cleveland BioLabs has been successful in gaining government grants with ~$80M awarded to date ($50M for development and $30M for potential procurement). As with most government grants, the company is reimbursed for completed work, which sums up to ~$40M for Cleveland BioLabs to date."Cleveland BioLabs closed at $1.40 on Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.